49Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Slovakia
Neuroscience Intelligence
Slovakia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #46 of 50 · Data maturity A · Research score 27.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
5Recruiting trials
15Publications
12Institutions
Executive interpretation
Slovakia ranks #46 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Sumitomo Pharma America, Inc.40 recruiting
Pfizer30 recruiting
AbbVie30 recruiting
Boehringer Ingelheim30 recruiting
UCB Pharma20 recruiting
Novo Nordisk A/S20 recruiting
Hoffmann-La Roche20 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.20 recruiting
Biotronik SE & Co. KG10 recruiting
Biohaven Therapeutics Ltd.10 recruiting
Disease activity
Epilepsy9trials
Parkinsons6trials
Alzheimers6trials
Depression4trials
Schizophrenia4trials
Migraine Headache2trials
Bipolar Disorder2trials
Multiple Sclerosis2trials
Other Neurology2trials
Stroke1trials
Research institutions
Comenius University BratislavaOpenAlexlinked institution
Slovak Society of CardiologyOpenAlexlinked institution
Institute of Neurobiology of the Slovak Academy of SciencesOpenAlexlinked institution
University of Pavol Jozef ŠafárikOpenAlexlinked institution
Slovak Academy of SciencesOpenAlexlinked institution
Institute of Virology of the Slovak Academy of SciencesOpenAlexlinked institution
Bratislava University of Economics and ManagementOpenAlexlinked institution
Constantine the Philosopher University in NitraOpenAlexlinked institution
Slovak University of Technology in BratislavaOpenAlexlinked institution
University of TrnavaOpenAlexlinked institution
Clinical evidence trail
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderRECRUITING
NCT06681480Transcranial Magnetic Stimulation (rTMS) for Refractory Focal EpilepsyACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)COMPLETED
NCT05211947A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTERMINATED
NCT05066230A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)TERMINATED
NCT04777409A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)COMPLETED
NCT04740671A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCOMPLETED
NCT04666610A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyCOMPLETED
Research evidence trail
PUBMEDClinical spectrum of epilepsy in children treated at a tertiary pediatric neurology center-A hospital-based cohort study.2026-10-01
PUBMEDDerivation of a new induced pluripotent stem cell line ORIONi004-A for modelling Duchenne muscular dystrophy.2026-09-01
OPENALEXSeveral lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants2024-03-14
OPENALEXReactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging2023-08-19
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.